SEC Form 4 · accession 0001628280-26-044712
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Camille L Bedrosian
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 22, 2026 · 5:02 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 18, 2026 | A | 5,925 | $0.00 | A | 22,225 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $35.87 | Jun 18, 2026 | A | 9,730 | A | — | Jun 18, 2036 | Common Stock | 9,730 | 9,730 | D |
Explanation of responses
- F1The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
- F2The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.